# Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

> **NCT06928584** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 221 (estimated)

## Conditions studied

- Locally Recurrent Rectal Cancer

## Interventions

- **RADIATION:** Conventional Radiotherapy
- **DRUG:** Capecitabine
- **DRUG:** 5-fluorouracil
- **DRUG:** folinic acid
- **DRUG:** Oxaliplatin
- **DRUG:** Irinotecan
- **DRUG:** Cetuximab
- **DRUG:** Bevacizumab
- **RADIATION:** Hypofractionated radiotherapy
- **DRUG:** PD-1 antibody

## Key facts

- **NCT ID:** NCT06928584
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-10
- **Primary completion:** 2030-03-10
- **Final completion:** 2030-03-10
- **Target enrollment:** 221 (ESTIMATED)
- **Last updated:** 2025-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06928584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06928584, "Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06928584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*